Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: meta-analysis of three treatment cohorts.
read more
Citations
Potential use of clinical polygenic risk scores in psychiatry – ethical implications and communicating high polygenic risk
Personalized repetitive transcranial magnetic stimulation temporarily alters default mode network in healthy subjects
Polygenic risk scores in psychiatry: Will they be useful for clinicians?
Polygenic risk scores for predicting outcomes and treatment response in psychiatry: hope or hype?
Major Depressive Disorder: Existing Hypotheses about Pathophysiological Mechanisms and New Genetic Findings
References
PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage Analyses
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010
Power and Predictive Accuracy of Polygenic Risk Scores
Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project
Related Papers (5)
Pharmacogenetics of antidepressant response: a polygenic approach
Genomic Prediction of Depression Risk and Resilience Under Stress
Dissection of major depressive disorder using polygenic risk scores for schizophrenia in two independent cohorts
Frequently Asked Questions (18)
Q2. What are the future works mentioned in the paper "Polygenic risk scores for major depressive disorder and neuroticism as predictors of antidepressant response: meta-analysis of three treatment cohorts" ?
However, with increasingly large and well-phenotyped cohorts available for analysis and more powerful GWAS outputs being produced, the authors tentatively conclude that more targeted prescribing of anti-depressants in MDD based on genetic profiles is a realistic prospect for the future.
Q3. What is the way to predict the response of patients to SSRIs?
Antidepressants such as Selective Serotonin Reuptake Inhibitors (SSRIs) are first line treatments for MDD but up to one third of patients do not respond satisfactorily [2, 3].
Q4. What were the profile scores for each trait?
Six profile scores were created for each trait using p value cut offs of p< 5 10−8, p< 5 10−5, p< 0.01, p< 0.05, p< 0.1 and p< 0.5.
Q5. What is the definition of a polygenic risk scoring?
Polygenic risk scoring (PRS) [5] is a method which allows an individual’s genetic loadingfor a trait to be calculated using genome-wide single nucleotide polymorphism (SNP) data and the output of genome-wide association study (GWAS) summary statistics from another study of the same or related phenotype.
Q6. What is the SSRI risk score for major depressive disorder?
Individual genetic variation may dictate likelihood of response to SSRIs [4] and, as such, stratifying patients into sub-groups based on genetic profiles may allow for more efficient targeting of treatment.
Q7. What was the direction of effect in all of the meta-analyses?
The direction of effect in all of the meta-analyses was negative (greater genetic loading for MDD and neuroticism associated with a smaller percentage drop in depression score at both four and eight weeks; S5 Table.
Q8. Why did the authors choose to investigate only the difference between the extreme ends of the PRS scale?
Due to low numbers and therefore the potential for noise within outcome data, instead ofassessing change in outcomes across the full range of polygenic scores the authors chose to investigate only the difference between the extreme ends of the PRS scale.
Q9. What is the significance of the PRS for MDD?
The authors estimate that a training sample of approximately 10,000 and a target sample of 5,000 individuals would give 60% power in a PRS of 100,000 SNPs that explain 10% of the variance in the training sample [22].
Q10. How many subjects were recruited for the PGRN-AMPS?
An initial batch of 530 subjects (N = 499 subjects of European ancestry that passed quality control) was genotyped for a pharmacogenomics GWAS of SSRIs [12].
Q11. What is the advantage of using PRS?
It is possible that the use of PRS is advantageous for clinical use over these methods as it allows for a whole-genome approach instead of focusing on specific SNPs, genes or regions.
Q12. What is the effect of PRS on MDD?
Here the authors test the hypothesis that PRS for MDD and PRS for neuroticism are associated with less favourable response to SSRIs, specifically citalopram and its active S-enantiomer escitalopram, in patients with MDD.
Q13. Why are the baseline scores higher in AMPS-1 and AMPS-2?
The baseline scores of the GENDEP cohort are higher than in AMPS-1 and AMPS-2 due to the cohort being scored using MADRS and not HAMD as is the case with AMP-1 and AMPS-2.
Q14. What is the current status of SSRIs in MDD?
Genotyping is not currently routine practice in clinical settings and the use of PRS to guide the use of SSRIs in MDD remains a long-term goal.
Q15. What is the R2 of the significant PRS term?
For the two AMPS-2 nominally significant results the R2 values of approximately 10%, suggesting that these PRSs could potentially be useful clinically.
Q16. What was the direction of effect in the MDD and neuroticism meta-analyses?
Although most of the findings were null, there was a direction of effect where higher PRS for MDD and higher PRS for neuroticism were associated with less favourable response to SSRIs.
Q17. What is the strength of this study?
An additional strength of this work is that all three cohorts systematically assessed treatment response at comparable time-points and in the context of the use of the same class of antidepressants, namely SSRIs.
Q18. How many patients were recruited for the PGRN-AMPS?
An additional 229 patients recruited in the PGRN-AMPS were subsequently genotyped for the International SSRI Pharmacogenomics Consortium (ISPC) GWAS [13].